Inovio Pharmaceuticals Debt 2024

Inovio Pharmaceuticals Aktienanalyse

What does Inovio Pharmaceuticals do?

Inovio Pharmaceuticals Inc. is a US biotechnology and pharmaceutical company specializing in the development of DNA vaccines and immunotherapies. It was founded in 1979 by Dr. Joseph Kim and is headquartered in Plymouth Meeting, Pennsylvania. Inovio began working on DNA-based vaccines in the late 1990s and developed the Electroporation technology, which facilitates the introduction of DNA molecules into cells. The company has expanded its capabilities over the years and is able to generate immune responses against a variety of viruses and bacteria. They have also made advancements in using their technology to combat cancer. Inovio's business model is based on licensing technologies and collaborating with partners such as pharmaceutical companies, government agencies, and academic institutions. They also offer services for the development and production of DNA-based vaccines for academic and industrial customers. Inovio is divided into different divisions, including DNA vaccines for infectious diseases and oncology, platform technology, and cancer immunotherapy. They offer a wide range of DNA vaccines for infectious diseases such as HPV, HIV, hepatitis B and C, as well as Lassa fever and Ebola. Inovio has also made significant progress in the development of DNA-based immunotherapies for cancer, using Electroporation technology to train and activate T-cells against cancer cells. In terms of products, Inovio has various products in different stages of clinical development, but they have not yet received FDA approval for any of their products. However, they have successfully conducted clinical trials for vaccines such as HPV, which has shown 90% efficacy against the virus. In conclusion, Inovio is a specialized company in the development of DNA-based vaccines and immunotherapy for cancer. Their Electroporation technology has led to significant breakthroughs, and they continue to pursue partnerships and further development. With their focus on research and development and advancing their technologies, it seems that Inovio is on a path of continued success. Inovio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Inovio Pharmaceuticals's Debt Structure

Inovio Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Inovio Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Inovio Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Inovio Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Inovio Pharmaceuticals stock

What is the debt of Inovio Pharmaceuticals this year?

Inovio Pharmaceuticals has a debt level of 2.46 USD this year.

What was the debt of Inovio Pharmaceuticals compared to the previous year?

The debt of Inovio Pharmaceuticals has increased by -108.28% compared to the previous year dropped.

What are the consequences of high debt for investors in Inovio Pharmaceuticals?

High debt can pose a risk for investors of Inovio Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Inovio Pharmaceuticals?

Low debt means that Inovio Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Inovio Pharmaceuticals affect the company?

An increase in debt of Inovio Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Inovio Pharmaceuticals affect the company?

A reduction in debt of Inovio Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Inovio Pharmaceuticals?

Some factors that can influence the debt of Inovio Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Inovio Pharmaceuticals so important for investors?

The debts of Inovio Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Inovio Pharmaceuticals take to change the debt?

To change the debt, Inovio Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Inovio Pharmaceuticals pay?

Over the past 12 months, Inovio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inovio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Inovio Pharmaceuticals?

The current dividend yield of Inovio Pharmaceuticals is .

When does Inovio Pharmaceuticals pay dividends?

Inovio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inovio Pharmaceuticals?

Inovio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Inovio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inovio Pharmaceuticals located?

Inovio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inovio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inovio Pharmaceuticals from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Inovio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Inovio Pharmaceuticals in the year 2023?

In the year 2023, Inovio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Inovio Pharmaceuticals pay out the dividend?

The dividends of Inovio Pharmaceuticals are distributed in USD.